1,3-bis(diphenylphosphono)propane | 42451-27-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,3-bis(diphenylphosphono)propane
• 英文别名: [3-diphenoxyphosphorylpropyl(phenoxy)phosphoryl]oxybenzene
• CAS: 42451-27-4
• 化学式: C₂₇H₂₆O₆P₂
• 分子量: 508.447
• InChiKey: GPXUKYQJSQAVQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  35
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(4-tert-butylthiazol-2-yl)-benzofuran-5-yl trifluoromethanesulfonate 、 1,3-bis(diphenylphosphono)propane 在 palladium diacetate 一氧化碳 、 三乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 2-(4-tert-butylthiazol-2-yl)benzofuran-5-carboxylate
  参考文献：
  名称：

  Thiazolylbenzofuran derivatives and pharmaceutical compositions

  摘要：

  本发明涉及新颖的噻唑基苯并呋喃衍生物，其具有公式（I），其中R1是低级烷基，L是单键或可被芳基、氧基或羟基取代的低级亚烷基，Q是可被一个或多个适当取代基取代的杂环基；或者是被芳基取代的低级烷氧基，该芳基被一个或多个适当取代基取代，并且至少一个是可被氰基、受保护的羧基、羧基、低级亚烷基、可被氧基取代的杂环基或可被羟基或低级烷氧基取代的胍基取代的低级烷氧基，或其盐，其具有作为白三烯和SRS-A拮抗剂或抑制剂的作用。

  公开号：

  US05994378A1

文献信息

• AMIDE DERIVATIVE
  申请人：Yamanoi Shigeo

  公开号：US20120129832A1

  公开（公告）日：2012-05-24

  Provided are a compound having an excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.

  提供一种具有优异降血糖作用的化合物，或其药用盐，以及一种具有优异治疗作用和/或预防作用的药物组合物，对于引起血糖水平增高的糖代谢异常导致的1型糖尿病、2型糖尿病等具有良好疗效。公开了一种由通用式(I)表示的化合物，或其药用盐。
• [EN] PYRROLOPYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS PYRROLOPYRIMIDINE
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2005085253A1

  公开（公告）日：2005-09-15

  According to the present invention, there is provided an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastro-intesinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine derivative represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  根据本发明，提供了一种针对CRF受体的拮抗剂，其作为治疗或预防代理用于CRF被认为参与的疾病，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物依赖、脑梗死、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、癫痫、皮肤炎、精神分裂症、疼痛等疾病具有有效性。以下式[I]所代表的吡咯吡嘧啶衍生物具有高亲和力对CRF受体，并对CRF被认为参与的疾病具有有效性。
• Pyrrolopyrimidine Derivatives
  申请人：Bischoff P. Francois

  公开号：US20070270588A1

  公开（公告）日：2007-11-22

  According to the present invention, there is provided an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastro-intestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine derivative represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  根据本发明，提供了一种CRF受体拮抗剂，作为治疗或预防CRF参与的疾病的药物，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物依赖、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、斑秃、肠易激综合征、睡眠障碍、癫痫、皮炎、精神分裂症、疼痛等。以下式[I]所表示的吡咯吡嘧啶衍生物对CRF受体具有高亲和力，并对CRF参与的疾病有效。
• AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH
  申请人：Walji Abbas M

  公开号：US20130059850A1

  公开（公告）日：2013-03-07

  The present invention is directed to certain Aza-Indole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.

  本发明涉及某些Aza-Indole衍生物，其可用作脂肪酸酰胺水解酶（FAAH）的调节剂和FAAH成像剂。本发明还涉及包含这些化合物作为活性成分的制药配方，以及这些化合物和它们的配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2862861A1

  公开（公告）日：2015-04-22

  A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group.

  通式(I)代表的化合物或其药理学上可接受的盐具有极佳的 LCAT 活化效果，可作为治疗或预防动脉硬化、动脉硬化性心脏病、冠心病（包括心力衰竭、心肌梗塞、心绞痛、心肌缺血、心血管紊乱和血管生成引起的再狭窄）的有效成分、和血管生成引起的再狭窄）、脑血管疾病（包括中风和脑梗塞）、外周血管疾病（包括糖尿病血管并发症）、血脂异常、低密度脂蛋白胆固醇血症或肾脏疾病，特别是抗动脉硬化药物，其中 R 是任选取代的芳基或任选取代的杂芳基。